Clinical trials for Mastocytosis

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Mastocytosis. For all clinical trials, go to clinical trials search

This list shows clinical trials for Mastocytosis

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Mastocytosis
Title Recruitment status Location
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies - NA Not Recruiting United Kingdom
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies - NA Not Recruiting United Kingdom
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, systemic mastocytosis, or hypereosinophilic syndrome - NA Not Recruiting United Kingdom
A phase II study to determine if the drug midostaurin taken orally twice daily is effective and safe in treating patients with Agressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease Not Recruiting United Kingdom
prospective,multi centre, randomized,double blind, placebo-controlled, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic,Indolent Systemic or Cutaneous Mastocytosis with handicap Not Recruiting United Kingdom
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies - NA Not Recruiting United Kingdom
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL and other hematological malignancies - NA Not Recruiting United Kingdom
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant CML in accelerated phase or blast crisis, relapsed/refractory Ph+ ALL, and other hematologic malignancies. Not Recruiting United Kingdom
Authorised United Kingdom
Authorised United Kingdom

Page last reviewed:

Next review due: